ATE475420T1 - Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten - Google Patents

Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten

Info

Publication number
ATE475420T1
ATE475420T1 AT06744549T AT06744549T ATE475420T1 AT E475420 T1 ATE475420 T1 AT E475420T1 AT 06744549 T AT06744549 T AT 06744549T AT 06744549 T AT06744549 T AT 06744549T AT E475420 T1 ATE475420 T1 AT E475420T1
Authority
AT
Austria
Prior art keywords
dopamine agonist
treating
ohss
preventing ovarian
syndrome
Prior art date
Application number
AT06744549T
Other languages
English (en)
Inventor
Antonio Pellicer-Martinez
Joan-Carlos Arce
Carlos Simon-Valles
Raul Gomez-Gallego
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Application granted granted Critical
Publication of ATE475420T1 publication Critical patent/ATE475420T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06744549T 2005-04-29 2006-04-24 Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten ATE475420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67616505P 2005-04-29 2005-04-29
PCT/IB2006/000989 WO2006117608A1 (en) 2005-04-29 2006-04-24 Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist

Publications (1)

Publication Number Publication Date
ATE475420T1 true ATE475420T1 (de) 2010-08-15

Family

ID=36699199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744549T ATE475420T1 (de) 2005-04-29 2006-04-24 Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten

Country Status (13)

Country Link
US (1) US8334298B2 (de)
EP (1) EP1874313B8 (de)
AT (1) ATE475420T1 (de)
CA (1) CA2605972C (de)
DE (1) DE602006015796D1 (de)
DK (1) DK1874313T3 (de)
ES (1) ES2349657T3 (de)
JO (1) JO2658B1 (de)
PL (1) PL1874313T3 (de)
PT (1) PT1874313E (de)
RU (1) RU2416410C2 (de)
TW (1) TWI315668B (de)
WO (1) WO2006117608A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
EP1952813A1 (de) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medikament zur Behandlung von Endometriose
KR101160225B1 (ko) 2007-02-01 2012-07-11 페링 인터내셔널 센터 에스 에이 자궁 내막증 치료용 약제
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
ITTO20070479A1 (it) * 2007-07-02 2009-01-03 Ceva Vetem S P A Composizione veterinaria iniettabile ad attivita' anti-prolattinica
EP3017809A1 (de) 2014-11-07 2016-05-11 Ferring B.V. Arzneimittelvorrichtung mit Quinagolid
RU2603319C1 (ru) * 2015-09-09 2016-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения больных с тяжелыми формами синдрома гиперстимуляции яичников
RU2637430C1 (ru) * 2016-06-29 2017-12-04 Федеральное государственное бюджетное учреждение "Эндокринологический научный центр" Министерства здравоохранения Российской Федерации Способ выбора тактики ведения пациентов с резистентными к консервативному лечению пролактин-секретирующими аденомами гипофиза на основе анализа индивидуальных особенностей фармакодинамики каберголина
EP4058140A4 (de) * 2019-11-15 2023-12-06 Martin Pharmaceuticals, Inc. Verfahren zur behandlung von aszites
US20240361338A1 (en) 2021-08-31 2024-10-31 Ferring B.V. Diagnosis and treatment of ectopic endometriosis
WO2024153752A1 (en) 2023-01-20 2024-07-25 Ferring B.V. Stereoselective synthesis of intermediates and synthesis of quinagolids
CN116806776B (zh) * 2023-08-03 2024-06-18 上海交通大学医学院附属第九人民医院 一种ohss小鼠模型及其构建方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88619I2 (fr) 1981-10-16 1995-07-10 Sandoz Ag QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
RU2143892C1 (ru) * 1997-05-27 2000-01-10 Ростовский научно-исследовательский институт акушерства и педиатрии Способ лечения синдрома гиперстимуляции яичников
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
EP1947195B1 (de) * 2005-09-13 2010-11-10 Neocodex, S.L. Verfahren zum in-vitro-nachweis einer veranlagung zur entwicklung von veränderungen der ovarienfunktion

Also Published As

Publication number Publication date
PL1874313T3 (pl) 2011-03-31
EP1874313B8 (de) 2010-09-01
US8334298B2 (en) 2012-12-18
RU2007139457A (ru) 2009-06-10
PT1874313E (pt) 2010-10-21
WO2006117608A1 (en) 2006-11-09
CA2605972C (en) 2011-08-02
EP1874313B1 (de) 2010-07-28
TW200724141A (en) 2007-07-01
TWI315668B (en) 2009-10-11
DK1874313T3 (da) 2010-11-15
JO2658B1 (en) 2012-06-17
ES2349657T3 (es) 2011-01-10
RU2416410C2 (ru) 2011-04-20
US20080293693A1 (en) 2008-11-27
CA2605972A1 (en) 2006-11-09
EP1874313A1 (de) 2008-01-09
DE602006015796D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
ATE475420T1 (de) Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
ECSP066362A (es) Inhibidores de quinesina mitótica.
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
MXPA05010873A (es) Metodos para el tratamiento de enfermedad de parkinson.
ATE446094T1 (de) Mitotische kinesin-hemmer
MX389904B (es) Metodos mejorados de control de la corrosion.
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA200601766A1 (ru) Производные имидазола
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
EA201490928A1 (ru) Способы лечения острых приступов подагры
MX2014008763A (es) Compuestos y metodos para tratar infecciones por candidosis y aspergillus.
PH12014500536A1 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
EA200500517A1 (ru) Лечение синдрома х замещёнными тетралинами и инданами
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
TN2009000486A1 (en) Raf inhibitors for the treatment of thyroid cancer
DE50210987D1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
DE502005010818D1 (de) Vorrichtung zum herstellen eines homogenen schnitttabakstroms

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1874313

Country of ref document: EP